Personal information

No personal information available

Activities

Collapse all

Employment (2)

Karolinska University Hospital: Stockholm, SE

(Bäckencancer)
Employment
Source: check_circle
Karolinska Institutet

Karolinska Institutet: Stockholm, SE

(Department of Oncology-Pathology)
Employment
Source: check_circle
Karolinska Institutet

Works (18)

Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination

J Clin Oncol
2023 | Journal article
DOI: 10.1200/JCO.22.00221
SOURCE-WORK-ID:

151666933

PMID: 35867951
Contributors: Arance, A; de la Cruz-Merino, L; Petrella, TM; Jamal, R; Ny, L; Carneiro, A; Berrocal, A; Márquez-Rodas, I; Spreafico, A; Atkinson, V et al.
Source: check_circle
Karolinska Institutet

Dynamics of plasma thymidine kinase activity in metastatic melanoma reflects immune checkpoint inhibitor efficacy

Acta Oncol
2022 | Journal article
DOI: 10.1080/0284186X.2022.2121615
SOURCE-WORK-ID:

150657388

PMID: 36083107
Contributors: Costa Svedman, F; Jalsenius, M; Grozman, V; Bergqvist, M; Söderdahl, F; Rotstein, S; Ny, L; Egyhazi Brage, S; Helgadottir, H
Source: check_circle
Karolinska Institutet

Plasma Thymidine Kinase Activity as a Novel Biomarker in Metastatic Melanoma Patients Treated with Immune Checkpoint Inhibitors

Cancers
2022 | Journal article
DOI: 10.3390/cancers14030702
SOURCE-WORK-ID:

148759779

PMID: 35158970
Contributors: Svedman, FC; Jalsenius, M; Hoeiom, V; Grozman, V; Bergqvist, M; Soederdahl, F; Eriksson, H; Rotstein, S; Ny, L; Ascierto, PA et al.
Source: check_circle
Karolinska Institutet

Proliferation and Immune Response Gene Signatures Associated with Clinical Outcome to Immunotherapy and Targeted Therapy in Metastatic Cutaneous Malignant Melanoma

Cancers
2022-07 | Journal article | Author
DOI: 10.3390/cancers14153587
Contributors: Fernanda; Ishani Das; Rainer Tuominen; Eva Darai Ramqvist; Veronica Höiom; Suzanne Egyhazi Brage
Source: check_circle
Multidisciplinary Digital Publishing Institute
grade
Preferred source (of 2)‎

[Overview of immune-related side effects from immune checkpoint inhibitors. Part 1: Gastrointestinal, lung and kidney toxicity]

Lakartidningen
2021 | Journal article
SOURCE-WORK-ID:

235080767

PMID: 35080767
Contributors: Villabona Lisa Villabona, L; Costa Svedman, F; Jovanovic, B; Kaneteg, B; Eberhardson, M; Magin, H; Ullenhag, G; Blomqvist, L; Helgadottir, H
Source: check_circle
Karolinska Institutet

Inflammation and Apolipoproteins Are Potential Biomarkers for Stratification of Cutaneous Melanoma Patients for Immunotherapy and Targeted Therapy

Cancer Res
2021 | Journal article
DOI: 10.1158/0008-5472.CAN-20-2000
SOURCE-WORK-ID:

146649635

PMID: 33574091
Contributors: Karlsson, MJ; Costa Svedman, F; Tebani, A; Kotol, D; Höiom, V; Fagerberg, L; Edfors, F; Uhlén, M; Egyhazi Brage, S; Maddalo, G
Source: check_circle
Karolinska Institutet

LEAP-004: updated data for lenvatinib plus pembrolizumab in patients with advanced melanoma and confirmed progressive disease on a prior PD-(L)1 inhibitor

Asia-Pac. J. Clin. Oncol.
2021 | Conference abstract
SOURCE-WORK-ID:

148143486
Contributors: Long, GV; de la Cruz-Merino, L; Petrella, TM; Jamal, R; Ny, L; Carneiro, A; Berrocal, A; Rodas, IM; Spreafico, A; Atkinson, V et al.
Source: check_circle
Karolinska Institutet

Lenvatinib (len) plus pembrolizumab (pembro) for patients (pts) with advanced melanoma and confirmed progression on a PD-1 or PD-L1 inhibitor: Updated findings of LEAP-004.

J. Clin. Oncol.
2021 | Conference abstract
DOI: 10.1200/JCO.2021.39.15_suppl.9504
SOURCE-WORK-ID:

148124646
Contributors: Arance, AM; de la Cruz-Merino, L; Petrella, TM; Jamal, R; Ny, L; Carneiro, A; Berrocal, A; Marquez-Rodas, I; Spreafico, A; Atkinson, V et al.
Source: check_circle
Karolinska Institutet

Plasma thymidine kinase activity (TKa) as a novel prognostic biomarker in metastatic melanoma.

J. Clin. Oncol.
2021 | Conference abstract
DOI: 10.1200/JCO.2021.39.15_suppl.9556
SOURCE-WORK-ID:

148106219
Contributors: Helgadottir, H; Svedman, FC; Jalsenius, M; Hoiom, V; Rotstein, S; Brage, SE; Grozman, V; Soderdahl, F; Ny, L; Bergqvist, M
Source: check_circle
Karolinska Institutet

Lenvatinib (len) plus pembrolizumab (pembro) for advanced melanoma (MEL) that progressed on a PD-1 or PD-L1 inhibitor: Initial results of LEAP-004

Ann. Oncol.
2020 | Conference abstract
DOI: 10.1016/j.annonc.2020.08.2274
SOURCE-WORK-ID:

144835549
Contributors: Fernandez, AMA; O'Day, SJ; Merino, LDLC; Petrella, T; Jamal, R; Ny, L; Carneiro, A; Berrocal, A; Marquez-Rodas, I; Spreafico, A et al.
Source: check_circle
Karolinska Institutet

Combining ERBB family and MET inhibitors is an effective therapeutic strategy in cutaneous malignant melanoma independent of BRAF/NRAS mutation status

Cell Death Dis
2019 | Journal article
DOI: 10.1038/s41419-019-1875-8
SOURCE-WORK-ID:

142177994

PMID: 31506424
Contributors: Das, I; Wilhelm, M; Höiom, V; Franco Marquez, R; Costa Svedman, F; Hansson, J; Tuominen, R; Egyhàzi Brage, S
Source: check_circle
Karolinska Institutet

Extracellular microvesicle microRNAs as predictive biomarkers for targeted therapy in metastastic cutaneous malignant melanoma

PLoS One
2018 | Journal article
DOI: 10.1371/journal.pone.0206942
SOURCE-WORK-ID:

139547053

PMID: 30399176
Contributors: Svedman, FC; Lohcharoenkal, W; Bottai, M; Brage, SE; Sonkoly, E; Hansson, J; Pivarcsi, A; Eriksson, H
Source: check_circle
Karolinska Institutet

Plasma-derived exosomal preparation and isolation of RNA

protocols.io
2018-09-21 | Journal article | Author
DOI: dx.doi.org/10.17504/protocols.io.tuienue
Contributors: Fernanda
Source: check_circle
protocols.io

Response to 'Surgical outcomes reflect the histological types of cutaneous malignant melanoma'

J Eur Acad Dermatol Venereol
2017 | Journal article
DOI: 10.1111/jdv.14024
SOURCE-WORK-ID:

136086825

PMID: 27785877
Contributors: Svedman, FC
Source: check_circle
Karolinska Institutet

Silencing FLI or targeting CD13/ANPEP lead to dephosphorylation of EPHA2, a mediator of BRAF inhibitor resistance, and induce growth arrest or apoptosis in melanoma cells

Cell Death Dis
2017 | Journal article
DOI: 10.1038/cddis.2017.406
SOURCE-WORK-ID:

136570243

PMID: 29048432
Contributors: Azimi, A; Tuominen, R; Costa Svedman, F; Caramuta, S; Pernemalm, M; Frostvik Stolt, M; Kanter, L; Kharaziha, P; Lehtiö, J; Hertzman Johansson, C et al.
Source: check_circle
Karolinska Institutet

Surgical outcomes in patients with cutaneous malignant melanoma in Europe - a systematic literature review

J Eur Acad Dermatol Venereol
2017 | Journal article
DOI: 10.1111/jdv.13950
SOURCE-WORK-ID:

135730022

PMID: 27580240
Contributors: Costa Svedman, F; Spanopoulos, D; Taylor, A; Amelio, J; Hansson, J
Source: check_circle
Karolinska Institutet

Stage-specific survival and recurrence in patients with cutaneous malignant melanoma in Europe - a systematic review of the literature

Clin Epidemiol
2016 | Journal article
DOI: 10.2147/CLEP.S99021
SOURCE-WORK-ID:

135078659

PMID: 27307765
Contributors: Svedman, FC; Pillas, D; Taylor, A; Kaur, M; Linder, R; Hansson, J
Source: check_circle
Karolinska Institutet

PROSTASIN, A POTENTIAL TUMOR MARKER IN OVARIAN CANCER- A PILOT STUDY

Clinics
2009 | Journal article
DOI: 10.1590/S1807-59322009000700006
SOURCE-WORK-ID:

119149549

PMID: 19606239
Contributors: Costa, FP; Batista Junior, EL; Zelmanowicz, A; Svedman, C; Devenz, G; Alves, S; da Silva, ASM; Garicochea, B
Source: check_circle
Karolinska Institutet
How many people are using ORCID?